DEVELOPMENTAL CANCER THERAPEUTICS

霍林斯癌症中心(HCC)发展癌症治疗(DCT)计划的科学目标是发现和表征将影响更有效癌症治疗开发的独特因素和途径，并通过使用原理验证、早期临床和相关科学研究将这些发现转化为临床应用。DCT项目由Kenneth D.Tew博士和Carolyn D.Britten医学博士共同领导。DCT计划围绕三个科学调查主题组织：细胞信号通路的�阐明。氧化还原和细胞应激反应的�调制。�开发小分子化疗药物。DCT计划的46名成员代表医学院和药学院内的12个部门，拥有87项有效的赠款/合同，总计1170万美元的癌症研究资金(770万美元来自同行评审资金，370万美元来自NCI)。2012年，DCT计划实施了65个早期阶段(试点)。I期、L/11期和II期)介入治疗临床试验，其中25例由研究人员启动；224例患者纳入了所有DCT计划介入治疗研究。在过去的五年中，DCT计划成员发表了305篇以癌症为重点的出版物，其中17%代表计划间合作，35%代表计划内合作，48%来自多学科合作。

The scientific goal of the Hollings Cancer Center (HCC) Developmental Cancer Therapeutics (DCT) Program is to discover and characterize unique agents and pathways that will impact the development of more effective cancer therapies and to translate these discoveries into clinical applications by using proof-of principle, early phase clinical and correlative science studies. The DCT Program is co-led by Kenneth D. Tew, PhD and Carolyn D. Britten, MD. The DCT Program is organized around three themes of scientific investigation: � Elucidation of Cellular Signaling Pathways. � Modulation of Redox and Cellular Stress Response. � Development of Small Molecule Chemotherapeutic Agents. The 46 members of the DCT Program, representing 12 departments within the College of Medicine and the College of Pharmacy, have 87 active grants/contracts totaling $11.7M in cancer research funding ($7.7 in peer-reviewed funding and $3.7M from the NCI). In 2012 the DCT Program implemented 65 early phase (pilot. Phase I, Phase l/ll, and Phase II) interventional treatment clinical trials, of which 25 were invesfigator initiated; 224 patients were enrolled onto all DCT Program interventional treatment studies. In the past five years, DCT Program members produced 305 cancer-focused publications with 17% of these representing inter-programmatic and 35% intra-programmatic collaborations and 48% from mulfi-insfitutional collaborations.